Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses NSCLC checkpoint inhibitors with the combinations of Epacadostat and IL-2 and IL-10. There has been a number of emerging signals with combination therapy over last year after exposure to first-line immune checkpoint inhibitors. Among the most significant data are in the combination of Epacadostat and IDO inhibitor with checkpoint inhibitors and the combinations of cytokine such as IL-2 and IL-10 with checkpoint inhibitors.
NSCLC Checkpoint Combinations Epacadostat, IL-2 & IL-10
